In a Nutshell
Selank is not FDA-approved, and the small Russian clinical literature behind it concerns a registered nasal formulation, not the products sold in the US.
Selank is a synthetic peptide derived from tuftsin, developed in Russia, where a 0.15% nasal-drop product is registered and a small clinical literature exists — including a 62-patient comparison against medazepam. That is more than an abstract research program, and less than FDA approval.
That history is route-specific: it concerns a nasal formulation, and does not establish the safety or effectiveness of injectable or differently compounded products sold under the Selank name in the US. It is usually sold alongside semax, which shares its research provenance.
Like semax, it has a real research history that does not transfer cleanly to a US clinical recommendation. The work was largely generated outside the methodological and regulatory framework FDA applies, has limited independent replication, and much of it is not accessible in English.
Selank is not an FDA-approved drug. It appears on FDA's list of bulk substances nominated but withdrawn, as "Selank acetate (TP-7)," with FDA stating it "lacks important information regarding any safety issues raised by selank acetate administered to humans" 1.
The more useful point is clinical rather than regulatory: it is marketed for anxiety, and anxiety is a diagnosable condition with treatments that work. Substituting an unapproved peptide for that is where the real cost lies.
What Selank Is
Tuftsin is a four-amino-acid peptide fragment with described immune-modulating activity. Selank is a synthetic heptapeptide built around it, modified to resist rapid breakdown.
Proposed mechanisms include modulation of GABA-related signaling, based mainly on animal and molecular work, along with effects on serotonin and BDNF. Selank's mechanism in humans has not been adequately characterized.
Worth correcting a common shorthand: most first-line anxiety medications do not work primarily through GABA. Benzodiazepines act at GABA-A receptors, but SSRIs and SNRIs — the usual first-line pharmacological treatments — work through serotonin and norepinephrine pathways. So a possible GABA-related effect does not by itself create a bridge to an SSRI or SNRI interaction.
Russian research examined it primarily in generalized anxiety disorder and related conditions, sometimes in comparison with benzodiazepines, with the claimed advantage of anxiolytic effect without sedation or dependence.
If that were established to US standards it would be genuinely significant, because sedation and dependence are the principal limitations of benzodiazepines. It has not been.
What the Evidence Shows
Evidence tier: C.
| Claim commonly made | What the evidence supports |
|---|---|
| Reduces anxiety | Russian clinical research exists; not replicated to US standards; FDA states it lacks safety information |
| No sedation or dependence unlike benzodiazepines | The claimed advantage; not established in trials meeting US standards |
| Improves focus and mood | Not established in controlled trials |
| Enhances cognition | Not established |
| Immune effects (via tuftsin) | Mechanistically plausible; clinical significance unclear |
The Same Caveat as Semax
Because selank and semax are sold together and share a research tradition, the same reasoning applies to both — and it is worth stating rather than assuming:
Evidence generated outside the United States can inform clinical judgment, and discounting it for its origin would be poor reasoning. What limits these particular studies is specific and nameable: size, controls, blinding, reporting quality, independent replication, uncertain product identity and route, the population studied, and how closely the endpoints match the use being marketed. FDA has separately stated it lacks the information needed to assess safety.
A foreign approval does not create an FDA approval — but the underlying evidence should be judged on its merits, not its nationality. The honest position here is neither "proven" nor "no evidence at all," but: not established to a standard that would support a US clinical recommendation, and generated for a nasal formulation rather than the products marketed in the US.
Anxiety Deserves an Actual Assessment
Regardless of suspected cause, thoughts of self-harm or a severe deterioration in mood need urgent help — call or text 988 in the US.
This section is the substance of the page.
Anxiety disorders are among the most treatable conditions in medicine, and the effective treatments are well established:
- Cognitive behavioral therapy has strong evidence and durable effects after treatment ends
- SSRIs and SNRIs are first-line pharmacological treatment, with substantial evidence
- Several medical conditions present as anxiety and are frequently missed — hyperthyroidism in particular, along with anemia, cardiac arrhythmias, and the effects of caffeine, alcohol and stimulant medication
- Perimenopause produces anxiety that is frequently misattributed, and responds to addressing the hormonal change directly. See perimenopause anxiety
- Sleep deprivation and untreated sleep apnea both generate and worsen anxiety symptoms
Treating anxiety with an unapproved peptide obtained online means none of the above gets excluded — and for the medical causes, that delay has consequences.
Safety and What Is Unknown
- Human safety data by US standards: FDA states it lacks important information 1
- Psychiatric medication: no reliable human interaction studies establish either safety or harm when Selank is combined with SSRIs, SNRIs, benzodiazepines or other psychiatric medicines. Tell the clinician managing those medicines — but the evidence does not support claiming a specific interaction from mechanism alone
- Long-term effects: unknown
- Pregnancy and breastfeeding: no data; not appropriate
- Product risk: most in circulation is research-grade — see peptide sourcing and quality
Red Flags — Seek Care Now
- Panic symptoms with chest pain, breathlessness or fainting — these need evaluation rather than assumption
- Palpitations, tremor, heat intolerance or unexplained weight loss — possible hyperthyroidism, which commonly presents as anxiety
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
- Fever, spreading redness or swelling at an injection site
On Dosing
This page does not provide dosing protocols. No adequate dose-finding study has established a regimen for the product, route and use marketed in the US. If you are using selank regardless, tell your clinician — particularly if you take any psychiatric medication.
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Thyroid function is part of that panel, and hyperthyroidism is a well-recognized and easily missed medical cause of anxiety symptoms. Laboratory testing can identify some contributors — thyroid dysfunction, anemia, nutrient deficiencies, metabolic abnormalities. It does not diagnose ADHD, anxiety disorders, sleep apnea or most autoimmune conditions; those need clinical history, examination and, where indicated, targeted testing or referral.
Can you get selank on prescription?
Selank is not FDA-approved, and FDA states it lacks the information needed to assess its safety in humans.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Semax — the peptide selank is usually sold with
- Perimenopause Anxiety — a common and treatable cause
- Are Peptides Legal in the US?
- The Downsides of Peptide Therapy
Frequently Asked Questions
What does Selank do?
Selank is a synthetic peptide derived from tuftsin, developed in Russia and studied there as an anxiolytic. Proposed mechanisms involve GABAergic and serotonergic signaling and BDNF. Its effects have not been established in trials meeting US standards, and it is not FDA-approved.
Is Selank good for anxiety?
Russian clinical research examined it for anxiety, sometimes against benzodiazepines. That research has limited independent replication and was not generated under FDA-equivalent standards. Anxiety has treatments — CBT, SSRIs and SNRIs — with substantial evidence, and several medical causes worth excluding first.
Selank vs Semax — what's the difference?
Both were developed in Russia and are usually sold together. Semax derives from ACTH(4–10) and is associated with focus, cognition and neuroprotection; selank derives from tuftsin and is associated with anxiety and stress. Neither is FDA-approved, and both appear on FDA's nominated-but-withdrawn list.
Does Selank cause sedation or dependence?
The claimed advantage over benzodiazepines is anxiolytic effect without sedation or dependence. That claim comes from the Russian research and has not been established in trials meeting US standards.
Is Selank FDA approved?
No. It appears on FDA's list of bulk substances nominated but withdrawn, as "Selank acetate (TP-7)," and FDA states it lacks important information regarding safety issues raised by administration to humans.
Can I take Selank with my antidepressant?
Not without clinical input — but be clear about why. There are no reliable human studies establishing either safety or harm for that combination. The concern is absence of data, not a demonstrated interaction. Discuss it with the clinician managing your medication.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- A. A. Zozulia, G. G. Neznamov, T. S. Siuniakov, N. V. Kost, M. V. Gabaeva, O. Yu. Sokolov, E. V. Serebriakova, O. A. Siranchieva, A. V. Andriushenko, E. S. Telesheva, et al., "[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]," Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, vol. 108, no. 4, pp. 38-48, 2008, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/18454096/. PMID: 18454096. [Accessed: Jul. 25, 2026]. Russian-language; preclinical/clinical standards differ from FDA requirements. ↩
- National Institute for Health and Care Excellence, "Generalised anxiety disorder and panic disorder in adults: management," Clinical guideline CG113, published Jan. 26, 2011, last updated Jun. 15, 2020, recommendations 1.2.17, 1.2.18, 1.2.23, 1.2.24. [Online]. Available: https://www.nice.org.uk/guidance/cg113 [Accessed: Oct. 5, 2026]. ↩
- R. Bunevicius, A. J. Prange Jr., "Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options," CNS Drugs, vol. 20, no. 11, pp. 897-909, 2006, [Online]. Available: https://doi.org/10.2165/00023210-200620110-00003. PMID: 17044727. [Accessed: Oct. 5, 2026]. ↩